Back to PFE Stock Lookup

Pfizer (PFE) – Press Releases

Dec 9, 2016 11:30 AM Akili and Pfizer Present Positive Data from Digital Biomarker Study to Detect Subtle Cognitive Changes in Healthy Subjects at Risk of Developing Alzheimer’s Disease
Dec 6, 2016 10:00 AM Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Dec 5, 2016 08:00 AM Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Dec 3, 2016 01:00 PM New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Dec 3, 2016 11:00 AM Spark Therapeutics and Pfizer Present Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting
Dec 1, 2016 10:00 AM Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
Dec 1, 2016 08:00 AM LYRICA® (pregabalin) Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint
Dec 1, 2016 08:00 AM IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery
Dec 1, 2016 08:00 AM IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery
Nov 30, 2016 04:01 PM Omnicell's Performance Center Integrates with Hospira's Infusion Pump Software
Nov 30, 2016 08:30 AM Pfizer Announces Positive Top-Line Results from the Pivotal Comparative REFLECTIONS B3271002 Study for PF-05280014, a Potential Biosimilar to Herceptin®1 (trastuzumab)
Nov 29, 2016 08:17 AM FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review
Nov 21, 2016 10:11 AM Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply to Retire
Nov 21, 2016 06:45 AM Pfizer Announces Expiration And Results Of Tender Offer For Any And All Of Its 6.200% Senior Notes Due March 15, 2019
Nov 18, 2016 02:55 PM Pfizer Announces Pricing of Tender Offer for Any and All of its 6.200% Senior Notes Due March 15, 2019
Nov 16, 2016 05:09 PM PALOMA-2 Phase 3 Study Published In The New England Journal Of Medicine Demonstrates Clinical Benefit Of Pfizer’s IBRANCE® (palbociclib) In First-Line ER+, HER2- Metastatic Breast Cancer
Nov 15, 2016 08:00 AM Pfizer Announces Results from Phase 3 OPAL Clinical Development Program Investigating XELJANZ® (Tofacitinib Citrate) for Psoriatic Arthritis
Nov 14, 2016 06:55 PM Pfizer Prices $6,000,000,000 Debt Offering
Nov 14, 2016 08:47 AM Pfizer Announces Tender Offer for Any and All of its 6.200% Senior Notes Due March 15, 2019
Nov 14, 2016 08:00 AM Pfizer to Collaborate with National Cancer Institute to Study Three Immunotherapy Agents Targeting Multiple Cancers
Nov 13, 2016 04:57 PM Landmark Study Demonstrates Pfizer’s Celebrex (Celecoxib)Has Similar Cardiovascular Risk As Compared To Prescription Doses Of Ibuprofen and Naproxen
Nov 11, 2016 06:00 AM Pfizer Announces Major Expansion of Humanitarian Assistance Program
Nov 10, 2016 07:59 AM Bristol-Myers Squibb and Pfizer to Deliver 12 New Eliquis® (apixaban) Presentations at American Heart Association (AHA) Scientific Sessions 2016
Nov 10, 2016 02:00 AM IBRANCE® (palbociclib) Receives Approval in European Union for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer
Nov 7, 2016 06:45 AM Pfizer to Present Additional Research For XELJANZ® (Tofacitinib Citrate) In Rheumatologic Diseases, Including Rheumatoid Arthritis and Psoriatic Arthritis
Nov 3, 2016 04:08 PM TherapeuticsMD Expands Commercial and Business Development Leadership
Nov 3, 2016 09:05 AM Spark Therapeutics and Pfizer Announce Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Sustained Therapeutic Levels of Factor IX Activity
Nov 2, 2016 06:45 AM Pfizer’s Prevenar 13® Receives Approval For Use in Infants and Children in China
Nov 1, 2016 06:45 AM PFIZER REPORTS THIRD-QUARTER 2016 RESULTS
Nov 1, 2016 06:30 AM Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor
Oct 31, 2016 03:00 AM European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Oct 21, 2016 11:55 AM FDA Approves Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Advanced Prostate Cancer
Oct 20, 2016 08:00 AM Debiopharm International SA Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer in Cancer Immunotherapy
Oct 19, 2016 06:02 PM CDC Advisory Committee on Immunization Practices Votes to Recommend New Dosing Schedule for Vaccination with TRUMENBA® (Meningococcal Group B Vaccine)
Oct 19, 2016 08:00 AM Pfizer Awarded Grant to Evaluate Vaccine to Protect Newborns Against Group B Streptococcus Infection
Oct 19, 2016 08:00 AM Pfizer Awarded Grant to Evaluate Vaccine to Protect Newborns Against Group B Streptococcus Infection
Oct 17, 2016 04:05 PM Pfizer Announces The U.S. Availability Of Biosimilar INFLECTRA® (infliximab-dyyb)
Oct 15, 2016 10:30 AM Pfizer to Present New Data on XELJANZ® (Tofacitinib Citrate) for Ulcerative Colitis at UEG Week 2016
Oct 11, 2016 12:00 PM Transgene Announces Collaboration with Merck and Pfizer to Evaluate the Combination of TG4001 with Avelumab in HPV-Positive Head & Neck Cancer in a Phase 1/2 Study
Oct 11, 2016 12:00 PM Transgene Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate the Combination of TG4001 with Avelumab in HPV-Positive Head & Neck Cancer in a Phase 1/2 Study
Oct 10, 2016 02:15 AM First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT® (sunitinib) Extended Disease Free Survival After Surgical Removal
Oct 9, 2016 10:30 AM Pfizer Presents Promising New Immunotherapy Combination Data With INLYTA® (axitinib) In Advanced Renal Cell Carcinoma (RCC)
Oct 6, 2016 07:45 AM ICU Medical Inc. to Acquire the Hospira Infusion Systems Business from Pfizer Inc. for $1 Billion in Cash and Stock
Sep 28, 2016 08:50 AM Pfizer Completes Acquisition of Medivation
Sep 28, 2016 06:00 AM Pfizer to Showcase Progress of Broad-Based Oncology Portfolio at European Society for Medical Oncology (ESMO) 2016 Congress
Sep 26, 2016 06:45 AM Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation
Sep 23, 2016 08:30 AM Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation
Sep 22, 2016 11:56 AM Pfizer Declares 30-Cent Fourth-Quarter 2016 Dividend
Sep 20, 2016 10:00 AM Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With Analysts
Sep 16, 2016 05:24 PM Pfizer Announces Positive Top-Line Results from REFLECTIONS B537-02 Study for PF-06438179 (infliximab-Pfizer) a Potential Biosimilar to Remicade® (infliximab)

Back to PFE Stock Lookup